UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): October 13, 2014

 

CHAMPIONS ONCOLOGY, INC.

 

(Exact name of registrant as specified in its charter)

 

 

Delaware	0-17263	52-1401755
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

 

 

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (201) 808-8400

 

Not applicable

(Former Name or Former Address if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

INFORMATION TO BE INCLUDED IN THE REPORT

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On October 13, 2014, Champion’s Oncology, Inc. (the “Company”) held its Annual Meeting of the Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows, there being no broker non-votes for any matter:

 

 

1. Election of Directors. The seven director nominees named in the Company's 2014 proxy statement were elected to serve for a one-year term expiring at the 2015 Annual Meeting of the Stockholders or until their successors are duly elected and qualified, based upon the following votes:

 

Director Nominee		Votes For				Votes Withheld
Joel Ackerman			43,205,432				17,524
Arthur G. Epker III			43,209,432				13,524
Daniel Mendelson			43,217,506				5,450
Ronnie Morris, M.D.			43,213,506				9,450
Abba David Poliakoff			43,207,506				15,450
David Sidransky			43,217,506				5,450
Scott Tobin			43,217,506				5,450

 

2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2015, was ratified as follows:

 

Votes For				Votes Against				Abstain
	27,190,066				16,032,790				100

 

3. Advisory Vote of the Compensation of the Company’s Named Executive Officers. The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2014 proxy statement, was approved by the following votes:

 

Votes For				Votes Against				Abstain
	43,173,032				41,575				8,349

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	CHAMPIONS ONCOLOGY, INC.
	(Registrant)
Date: October 13, 2014	By:	/s/ Joel Ackerman
		Joel Ackerman Chief Executive Officer